Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
57.95
+2.59 (4.68%)
At close: Mar 6, 2026
SHA:688513 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 971.4 | 781.23 | 830.97 | 1,051 |
Trading Asset Securities | - | 452.35 | 741.78 | 516.36 | 453.84 |
Cash & Short-Term Investments | 1,566 | 1,424 | 1,523 | 1,347 | 1,505 |
Cash Growth | 10.00% | -6.52% | 13.04% | -10.45% | -7.43% |
Accounts Receivable | - | 288.44 | 177.7 | 180.92 | 126.73 |
Other Receivables | - | 0.44 | 0.66 | 1.25 | 0.17 |
Receivables | - | 288.88 | 178.36 | 182.17 | 126.9 |
Inventory | - | 190.09 | 160.98 | 140.87 | 103.68 |
Prepaid Expenses | - | 4.22 | 4.1 | 12.78 | 3.2 |
Other Current Assets | - | 21.76 | 16.41 | 25.97 | 40.76 |
Total Current Assets | - | 1,929 | 1,883 | 1,709 | 1,779 |
Property, Plant & Equipment | - | 1,249 | 1,255 | 1,141 | 874.59 |
Long-Term Investments | - | 80.71 | 81.08 | 46.66 | - |
Other Intangible Assets | - | 35.6 | 34.46 | 34.61 | 33.71 |
Long-Term Deferred Tax Assets | - | 11.5 | 8.57 | 8.73 | 12.16 |
Long-Term Deferred Charges | - | 77.51 | 54.92 | 45.36 | 12.35 |
Other Long-Term Assets | - | 16.73 | 29.89 | 32.09 | 63.39 |
Total Assets | - | 3,400 | 3,347 | 3,018 | 2,775 |
Accounts Payable | - | 144.35 | 180.94 | 156.86 | 203.92 |
Accrued Expenses | - | 266.85 | 218.97 | 190.72 | 156.1 |
Short-Term Debt | - | 74.44 | 180.95 | 105.29 | 20.02 |
Current Portion of Long-Term Debt | - | 3.67 | 2.93 | - | - |
Current Income Taxes Payable | - | 4.62 | 3.34 | 1.46 | 2.71 |
Current Unearned Revenue | - | 38.28 | 31.98 | 28.71 | 10.99 |
Other Current Liabilities | - | 64.12 | 41.98 | 46.35 | 38.72 |
Total Current Liabilities | - | 596.32 | 661.09 | 529.39 | 432.46 |
Long-Term Debt | - | 35.93 | 39.6 | - | - |
Long-Term Unearned Revenue | - | 68.25 | 41.18 | 42.81 | 51.03 |
Long-Term Deferred Tax Liabilities | - | 1.7 | 1.46 | 0.88 | 0.12 |
Total Liabilities | - | 702.21 | 743.33 | 573.08 | 483.6 |
Common Stock | - | 176.53 | 120.09 | 120.09 | 120.09 |
Additional Paid-In Capital | - | 1,388 | 1,444 | 1,444 | 1,444 |
Retained Earnings | - | 1,208 | 1,040 | 880.3 | 727.45 |
Treasury Stock | - | -76.22 | -1.59 | - | - |
Comprehensive Income & Other | - | 1.02 | 0.99 | 0.02 | 0.07 |
Shareholders' Equity | 2,866 | 2,698 | 2,603 | 2,444 | 2,292 |
Total Liabilities & Equity | - | 3,400 | 3,347 | 3,018 | 2,775 |
Total Debt | 133.23 | 114.04 | 223.48 | 105.29 | 20.02 |
Net Cash (Debt) | 1,433 | 1,310 | 1,300 | 1,242 | 1,485 |
Net Cash Growth | 9.41% | 0.78% | 4.63% | -16.33% | -6.35% |
Net Cash Per Share | 8.25 | 7.48 | 7.34 | 7.03 | 8.43 |
Filing Date Shares Outstanding | 166.7 | 174.08 | 174.93 | 176.53 | 176.53 |
Total Common Shares Outstanding | 174.35 | 174.08 | 176.49 | 176.53 | 176.53 |
Working Capital | - | 1,332 | 1,222 | 1,180 | 1,347 |
Book Value Per Share | 16.44 | 15.50 | 14.75 | 13.85 | 12.98 |
Tangible Book Value | 2,832 | 2,662 | 2,569 | 2,410 | 2,258 |
Tangible Book Value Per Share | 16.24 | 15.29 | 14.56 | 13.65 | 12.79 |
Buildings | - | 775.81 | 724.27 | 487.54 | 152.45 |
Machinery | - | 678.03 | 661.8 | 673.35 | 279.81 |
Construction In Progress | - | 189.56 | 186.26 | 231.12 | 637.88 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.